Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Abstract Background This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation. Methods Patients with type 2 diabetes and albuminuria were randomized to dapagliflozin, dapagliflozin and saxagliptin, or placebo. We...

Full description

Bibliographic Details
Main Authors: Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Cardiovascular Diabetology
Subjects:
Anemia
Ferritin
Hematopoiesis
Interleukin-6
Iron metabolism
Monocyte chemoattractant protein-1
Online Access:https://doi.org/10.1186/s12933-023-02027-8

Internet

https://doi.org/10.1186/s12933-023-02027-8

Similar Items